New Multi-Particle Systems for Colon-Targeted Meloxicam
- Eva Navarro Ruiz 1
- Covadonga Álvarez Álvarez 3
-
Juan J García Rodríguez
12
-
Santiago Torrado Durán
12
-
Susana Torrado Durán
12
-
de la Torre Iglesias PM
12
- 1 Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid 28040, Spain
- 2 Institute of Industrial Pharmacy, Complutense University of Madrid, Madrid 28040, Spain
- 3 Department of Parasitology, Faculty of Pharmacy, Complutense University of Madrid, Madrid 28040, Spain
ISSN: 1920-4159
Año de publicación: 2016
Volumen: 8
Número: 3
Páginas: 1-3
Tipo: Artículo
Otras publicaciones en: Journal of Applied Pharmacy
Objetivos de desarrollo sostenible
Resumen
Meloxicam (MLX) is a non-steroidal anti-inflammatory drug (NSAIDs) from the Oxicam family. This group of NSAIDs has been highly used in the treatment of rheumatoid arthritis and post-operative inflammation and is known as good antioxidants. Recently, their activity in chemoprevention, chemo-suppression, UV-sensitization and UVprotection was also identified. MLX has been described as a COX-2 selective inhibitor. Its use has some advantages regarding to its selectivity, namely, less adverse effects as gastrointestinal aggression and anticlotting activity. As MLX is better absorbed in colon and its properties against colon cancer and colonic inflammatory diseases are being studied, it is interesting to investigate a new MLX formulation for colonic delivery. We are studying the solubility and the dissolution of different combined formulations at pH 1.2, 6.8 and 7.4 to mimic their absorbance in the colon. These formulations are composed by different excipients that provide pH and time-dependent deliveries such as cellulose (Metolose®) and methacrylic acid esters with quaternary ammonium groups (EUDRAGIT® RS 30D, EUDRAGIT® FS 30D and EUDRAGIT® NM 30D).